Cost-Utility of Group Acceptance and Commitment Therapy for Fibromyalgia Versus Recommended Drugs: An Economic Analysis Alongside a 6-Month Randomized Controlled Trial Conducted in Spain (EFFIGACT Study)
| Autor: | Lance M. McCracken, Jaume Aguado, Albert Feliu-Soler, María Teresa Peñarrubia-María, Antoni Serrano-Blanco, Francesco D'Amico, Martin Knapp, Javier García-Campayo, Juan V. Luciano |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Adult
Male Marginal cost medicine.medical_specialty Fibromyalgia Cost effectiveness Cost-Benefit Analysis Pregabalin Duloxetine Hydrochloride Acceptance and commitment therapy law.invention 03 medical and health sciences Indirect costs 0302 clinical medicine Quality of life Randomized controlled trial law Outcome Assessment Health Care Health care Humans Medicine Quality-adjusted life years 030212 general & internal medicine Acceptance and Commitment Therapy health care economics and organizations Cost-utility Analgesics business.industry Middle Aged Quality-adjusted life year Anesthesiology and Pain Medicine Neurology Spain RA Public aspects of medicine Psychotherapy Group Physical therapy Cost-effectiveness Female Neurology (clinical) business 030217 neurology & neurosurgery |
| Zdroj: | Luciano, J V, D’Amico, F, Feliu-Soler, A, McCracken, L M, Aguado, J, Peñarrubia-María, M T, Knapp, M, Serrano-Blanco, A & García-Campayo, J 2017, ' Cost-utility of Group Acceptance and Commitment Therapy for Fibromyalgia versus recommended drugs: An economic analysis alongside a 6-month randomised controlled trial conducted in Spain (EFFIGACT study) ', JOURNAL OF PAIN . https://doi.org/10.1016/j.jpain.2017.03.001 |
| ISSN: | 1526-5900 |
| DOI: | 10.1016/j.jpain.2017.03.001 |
| Popis: | The aim of this study was to analyze the cost utility of a group-based form of acceptance and commitment therapy (GACT) in patients with fibromyalgia (FM) compared with patients receiving recommended pharmacological treatment (RPT) or on a waiting list (WL). The data were derived from a previously published study, a randomized controlled trial that focused on clinical outcomes. Health economic outcomes included health-related quality of life and health care use at baseline and at 6-month follow-up using the EuroQoL and the Client Service Receipt Inventory, respectively. Analyses included quality-adjusted life years, direct and indirect cost differences, and incremental cost effectiveness ratios. A total of 156 FM patients were randomized (51 GACT, 52 RPT, 53 WL). GACT was related to significantly less direct costs over the 6-month study period compared with both control arms (GACT €824.2 ± 1,062.7 vs RPT €1,730.7 ± 1,656.8 vs WL €2,462.7 ± 2,822.0). Lower direct costs for GACT compared with RPT were due to lower costs from primary care visits and FM-related medications. The incremental cost effectiveness ratios were dominant in the completers’ analysis and remained robust in the sensitivity analyses. In conclusion, acceptance and commitment therapy appears to be a cost-effective treatment compared with RPT in patients with FM. Perspective Decision-makers have to prioritize their budget on the treatment option that is the most cost effective for the management of a specific patient group. From government as well as health care perspectives, this study shows that a GACT is more cost effective than pharmacological treatment in management of FM. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|